Recombinant Human DMBT1 protein(Met1-Ser220), His-tagged

• Cat.No.: DMBT1-3231H
• Product Overview: Recombinant Human DMBT1 (NP_004397.2) (Met 1-Ser 220) was expressed in HEK293, fused with a polyhistidine tag at the C-terminus.

Specification

• Species: Human
• Source: HEK293
• Tag: His
• Protein Length: 1-220 a.a.
• Form: Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.
• Bio-activity: 1. Measured by its binding ability in a functional ELISA. 2. Immobilized recombinant human Galectin-3 at 10 μg/ml (100 μl/well) can bind biotinylated DMBT1-His with a linear range of 0.06-1.0 μg/ml.
• Molecular Mass: The recombinant human DMBT1 consists of 211 amino acids and has a predicted molecular mass of 22.6 kDa. The apparent molecular mass of rh DMBT1 is approximately 35-45 kDa in SDS-PAGE under reducing conditions due to glycosylation.
• Endotoxin: < 1.0 EU per μg of the protein as determined by the LAL method
• Purity: > 95 % as determined by SDS-PAGE
• Storage: Samples are stable for up to twelve months from date of receipt at -20°C to -80°C. Store it under sterile conditions at -20°C to -80°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
• Reconstitution: It is recommended that sterile water be added to the vial to prepare a stock solution of 0.2 ug/ul. Centrifuge the vial at 4°C before opening to recover the entire contents.

Gene Information

• Gene Name: DMBT1 deleted in malignant brain tumors 1 [ Homo sapiens ]
• Official Symbol: DMBT1
• Synonyms: DMBT1; deleted in malignant brain tumors 1; deleted in malignant brain tumors 1 protein; GP340; muclin; SAG; gp-340; hensin; glycoprotein 340; salivary agglutinin; surfactant pulmonary-associated D-binding protein; FLJ61058; MGC164738
• Gene ID: 1755
• mRNA Refseq: NM_004406
• Protein Refseq: NP_004397
• MIM: 601969
• UniProt ID: Q9UGM3

Case Study

Case 1: Ma N, et al. Cell Biochem Funct. 2020

DMBT1 suppresses ovarian cancer progression by inhibiting galectin-3/PI3K/AKT signaling, reducing cell proliferation, migration, and MMP expression while enhancing cisplatin sensitivity. Overexpression of DMBT1 in SKOV3 cells reverses oncogenic phenotypes, positioning it as a tumor suppressor and potential biomarker for novel therapeutic strategies in ovarian cancer treatment.

Fig1. The protein expression level of DMBT1 in a human normal ovarian epithelial cell line (NOEC) and four human ovarian cancer cell lines was measured using western blot assay.

Fig2. The interaction between DMBT1 and galectin-3 was verified by IP assay.

Case 2: Li J, et al. PLoS Pathog. 2017

Human tear fluid inhibits Pseudomonas aeruginosa corneal infection via DMBT1-mediated suppression of bacterial twitching motility, independent of antimicrobial activity. DMBT1 binds pili to block surface traversal and reduce disease pathology in vitro and in vivo, revealing a non-canonical mucosal defense mechanism targeting virulence rather than bacterial viability.

Fig1. Purified DMBT1 from saliva inhibited P. aeruginosa PAO1 twitching velocity and colony size expansion in a dose-dependent manner.

Fig2. Western immunoblot of PilA expression in P. aeruginosa PAO1 after DMBT1 (100 ng/μl) treatment on twitching media for 4 h.

Application

1. Therapeutic Potential of Recombinant DMBT1 Protein in Oncology and Infection Control Recombinant DMBT1 protein demonstrates dual therapeutic roles in suppressing tumor progression and combating bacterial infections. In ovarian cancer, it inhibits galectin-3/PI3K/AKT signaling, reducing cell proliferation, migration, and enhancing cisplatin sensitivity. Concurrently, DMBT1 disrupts Pseudomonas aeruginosa virulence by binding bacterial pili to block corneal infection in vivo, offering a non-antimicrobial defense strategy. These multifunctional properties position recombinant DMBT1 as a novel therapeutic agent for cancers and antibiotic-resistant infections. 2. Diagnostic and Biomarker Applications in Precision Medicine As a biomarker, recombinant DMBT1 aids in stratifying high-risk ovarian cancer patients and monitoring therapeutic responses. Its downregulation in tumors correlates with aggressive phenotypes, enabling early detection via ELISA or liquid biopsy platforms. In infectious diseases, DMBT1 levels in mucosal fluids (e.g., tears, saliva) predict susceptibility to bacterial colonization, guiding prophylactic interventions. Integration into diagnostic workflows supports precision oncology and infection management by linking molecular profiles to clinical outcomes. 3. Advancing Mechanistic Research and Drug Development Recombinant DMBT1 facilitates high-throughput screens to identify small-molecule modulators targeting galectin-3 or bacterial pili interactions. Structural studies reveal binding interfaces critical for tumor suppression and anti-infective activity, informing the design of peptide mimetics or biologics. Collaborative efforts explore its synergy with immunotherapy or antibiotics, bridging oncology and infectious disease research. These applications underscore DMBT1’s potential in next-generation therapeutics and biomarker-driven clinical trials.

Fig1. DMBT1 links gut inflammation to epithelial differentiation by binding pathogens and factors. (Weiqun Kang 2003)